Stem Cell Clinic

Stem Cell Therapy for Dogs and Cats Is Innovative at Stafford Veterinary Hospital – By MARIA SCANDALE – The SandPaper

By adminJanuary 17, 2020Adult Stem Cells

Stafford Township, NJ Stem cell therapy is an incredible process for healing damaged tissue, so it seems remarkable that it is availablefor petsright here in Manahawkin. Stafford Veterinary Hospital, at 211 North Main St., began offering the advanced treatment in 2019, under the direction of Michael Pride, medical director at the facility.

There, stem cell therapy is most commonly applied to osteoarthritis, but can also be used in dogs suffering from hip dysplasia and ligament and cartilage injuries, as well as mobility ailments and some chronic inflammatory issues such as inflammatory bowel disease and chronic kidney disease, which is common in cats.

Stem cell therapy is actually the only thing that can help to reverse the process of arthritis, Pride said. Everything else is a Band-Aid.

This process can actually help to rebuild cartilage and really reduce inflammation without the need of using aspirin-type medications, Pride said. Its a newer technology that we can use to avoid chronic use of medications, which might actually be detrimental in the long term for the liver or kidneys.

Stem cell therapy treats the source of the problem by offering the ability to replace damaged cells with new ones, instructs the website staffordvet.com.

Stem cells are powerful healing cells in the pets body that can become other types of cells. For example, in the case of arthritis, stem cells can become new cartilage cells and have natural anti-inflammatory properties, thus reducing pain and increasing mobility.

The stem cells are your primary structural cell for all other cells in the body; they can differentiate into almost any other cell, explained Pride. Were processing it down into that primordial stem cell; were activating it, and were injecting it into where it needs to be, and it just starts taking on the characteristics of the cells around it.

Table-top machines from MediVet Biologics are the first Adipose Stem Cell therapy kits for in-clinic use, a major advancement. Stem cell therapy for animals has been commercially available since 2004. MediVet pioneered in-clinic treatment options around 2010.

Pride believes Stafford Veterinary Hospital offers the only such treatment in the immediate area; another is in Egg Harbor Township, Atlantic County.

Were always trying to figure out different ways to help the patient without hurting them, he said while petting a kitten that had been a patient for another type of treatment.

As stem cell therapy is more in the news regarding humans, a pet owners first question might be where the stem cells come from that are used in the process. The answer: from fat tissue of the pet itself, extracted and processed the same day.

As the therapy has been refined in the last decade, it has actually started to become a lot easier, more cost-effective more recently, said Pride, since weve been able to process fat tissue instead of actually getting bone marrow.

Fat tissue actually has a much higher concentration of adult stem cells than bone marrow does, so its less painful for the patient, they heal a lot easier, and we dont have to process it in a different facility.

Everything comes from the animal, and we give it back to the animal. Nothing comes from another animal. We dont have to worry about them rejecting the sample; its their own tissue, and were giving it back to them.

The pet typically goes home the same day after about eight hours. First, X-rays and a consultation with the veterinarian can determine whether the pet is a candidate for the treatment.

A pet owner may not even know that their animal has arthritis.

Cats have a lot of inflammatory issues that they tend to be very good at hiding, said Pride. A lot of people dont realize that they have arthritis. They think, oh, my cats just getting older; hes not jumping as much; hes not as strong; hes just sleeping most of the day, but actually he has arthritis. Its very difficult to diagnose in cats. A lot of times you end up having to do X-rays to find where the arthritic joints happen to be.

An inch-and-a-half incision is the minor surgery that harvests the fat tissue from the belly while the pet is anesthetized. For a cat, about 20 gramsare extracted. For a large dog, about 40 gramsare needed. While the pet is recovering from the incision surgery, the veterinary hospital is processing the sample. When the sample is ready, the pet is sedated because we then have to give them the joint injections. Then we can reverse the sedation, and they go home.

We asked the doctor if the process always works. He gave the example that on average, a dog such as a boxer that was hobbled is now able to walk without seeming like its painful. In an extreme positive case, a dog that had been barely walking might be bouncing all over the place in two months.

It doesnt always work to the extent that we would love it to, but we usually notice that there is a positive effect from it, Pride remarked. Every patient will be different in what they experience.

For the same reason that everyones situation is going to be different, cost of treatment was not given for this story.

It generally takes about 30 to 60 days for relief to show, the veterinarian said, and the animals progress will be monitored.

On average, results last about 18 months to two years before more stem cells might have to be injected. The procedure takes about an hour.

The nice thing is once we collect those stem cells (from the first procedure), we can bank the leftovers they are cryogenically stored at MediVet corporate headquarters in Kentucky and we dont have to go through the initial anesthetic surgery, said Pride.

Stem cell therapy is one of several innovative modalities available at Stafford Veterinary Hospital. Laser therapy, acupuncture and holistic medicine are others. Care for exotic pets is available, as is emergency pet care.

Visit the website staffordvet.com or call 609-597-7571 for more information on general and specialized services, including: vaccinations, microchipping, spayingand neutering, dental care, wellness exams, dermatology, gastrology, oncology, opthalmology, cardiology, soft-tissue surgery, ultrasound, radiography, nutrition, parasite control, boarding, laborand delivery, end-of-life care, and cremation.

Stafford Veterinary Hospital has been in business since 1965, founded by Dr. John Hauge. Today, five highly skilled veterinarians are on staff, and a satellite, Tuckerton Veterinary Clinic, is at 500 North Green St. in Tuckerton.

Pride has been medical director at Stafford Veterinary Hospital since 2008. He attended Rutgers University, then earned his Veterinary of Medicine degree at Oklahoma State University.

The mild-mannered doctor feels a great rewardfrom treating animals that cant speak for themselves when they feel bad.

These guys, theyre always thankful; you can see what they think, he said of treated pets. The turnaround in their attitude, the turnaround in their ability to be more comfortable, you can see it in their faces; you can see it in their actions. You learn to read animals over time.

Its knowing that were helping those who cant help themselves, he added, and you can see it in them; thats the most gratifying.

mariascandale@thesandpaper.net

Go here to read the rest:
Stem Cell Therapy for Dogs and Cats Is Innovative at Stafford Veterinary Hospital - By MARIA SCANDALE - The SandPaper

Why stem cells could be the medical innovation of the century – World Economic Forum

By adminJanuary 17, 2020Stem Cell Clinics

Right now, your bodys stem cells are working hard replacing your skin every two weeks, creating new red and white blood cells and completing thousands of other tasks essential to life. They are your own personalized fountain of youth.

Scientists generally agree that a stem cell should be able to do both of the following:

One theory of ageing suggests that between the ages of 30 and 50, our stem cells reach a turning point and start to decline in number and function. This results in the typical features associated with ageing.

There does not seem to be a single discoverer of stem cells. Accounts date back to the 1800s and even further, but the first successful medical procedure was a bone marrow transfusion in 1939. Advances in immunology led to donor matching, initially via siblings and close relatives. Unrelated donor matching flourished in the 1970s, alongside donor registries.

In the 1980s, scientists identified embryonic stem cells in mice, leading to the 1997 cloning of Dolly the Sheep. This created immense interest for human and medical applications and a backlash in the US as federal R&D funding was essentially halted in 2001.

In 2012, a Nobel Prize was awarded for the earlier discovery of induced pluripotent stem cells (iPS). Essentially, they return potency and self-renewal properties to mature non-stem cells, essentially making them act like stem cells again.

In the decade between 2010 and 2019, the first wave of stem cell start-ups emerged, alongside R&D programmes at many large pharmaceutical companies, leading to innovation and the first human clinical trials for iPS and other related therapies.

According to Q3 2019 data from the Alliance for Regenerative Medicine, there are 959 regenerative medicine companies worldwide sponsoring 1,052 active clinical trials; 525 of these companies are in North America, 233 in Europe and Israel, and 166 in Asia. In aggregate, $7.4 billion has been invested in regenerative medicine companies in 2019; $5.6 billion of which has been dedicated to gene and gene-modified cell therapy, $3.3 billion in cell therapy, and $114 million in tissue engineering.

Overview of the cancer stem cells market

Perhaps most excitingly, curative therapies are hitting the market and the results are astonishing: 60% of Acute Lymphoblastic Leukemia patients taking Novartis Kymirah showed a complete response (no traces of cancer) and were declared in full remission. Meanwhile, 75% of patients with Transfusion-Dependent -Thalassaemia treated with bluebird bios Zynteglo achieved independence from transfusions. Perhaps most astonishingly, 93% of spinal muscular atrophy patients treated with Novartis Zolgensma were alive without permanent ventilation 24 months after treatment. We should expect more medical breakthroughs in the coming years.

New science, new start-ups: several companies in the sector have gone public or been acquired. These exits led to the recycling of talent and capital into new companies. Because the science and commercial systems have also advanced, the companies in the next wave are pursuing bigger challenges, driving innovation, with even greater resources.

Patients are eager: the current market for stem cell therapies is growing at 36% per year, though it will rapidly expand when a breakthrough occurs toward the treatment of a non-communicable disease (such as cancer, diabetes, heart disease) or a lifestyle factor (for example, growing hair in the correct places, expanding cognitive abilities or increasing healthy lifespan).

New R&D models: funding is flowing into the sector from large companies, VC funds, and institutions such as the California Institute for Regenerative Medicine (CIRM) and New York State Stem Cell Science programme (NYSTEM). Some of the leading university R&D platforms include the Center for the Commercialization of Regenerative Medicine in Toronto, the Stanford Institute for Stem Cell Biology and Regenerative Medicine, the Oxford Stem Cell Institute, and most notably, the Harvard Stem Cell Institute (HSCI).

Founded in 2004, HSCI has established a phenomenal track record. It provided the first $200,000 in funding to Derrick Rossis lab, which inspired the largest biotech IPO to date. HSCI scientists were also co-founders or principals in the three most prominent gene-editing companies (CRISPR Tx, Intellia and Editas), the combined $1.55-billion True North/iPierian acquisitions and the recent $950-million acquisition of Semma Tx, Frequency Tx, Fate Tx, Epizyme Inc., and Magenta Tx.

For the casual investor, Evercore ISI is building a Regenerative Medicine Index, which may be the simplest way to build a portfolio. For institutions and those with deeper pockets, regenerative medicine funds are forming, including the Boston-centric Hexagon Regenerative Medicine Fund, which aims to create companies out of the Harvard Stem Cell Institute.

Caveat emptor. Though patients needs are immediate, those seeking treatments should think very carefully about the risks. There are many dubious clinics touting expensive stem cell treatments and some patients have experienced horrifying complications. Dr. Paul Knoepfler of UC-Davis has written a practical and scientifically accurate guide, a strongly recommended read if you or a family member are considering treatment or a clinical trial.

The leading causes of death in 1900 were mostly infectious/communicable diseases. While the prevalence of most causes has diminished, the largest increases include heart disease (+40%) and cancer (+300%). Granted, this is partly due to doubling life expectancy and a lack of death from other causes. However, given time and resources, scientists and physicians may cure these challenging diseases.

Total disease burden by disease or injury

Today, six of the seven leading causes of death are non-communicable diseases (heart disease, stroke, lung diseases, cancer, Alzheimers disease and diabetes). Based on the early promise mentioned above, regenerative medicine may be our best hope to solve the great non-communicable diseases of our time, and perhaps the single most transformative medical innovation in a century.

License and Republishing

World Economic Forum articles may be republished in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Astellas and Adaptimmune team up in CAR-T development – European Biotechnology

By adminJanuary 15, 2020Induced Pluripotent Stem Cells

Adaptimmune Therapeutics plc and Japanese Astellas Pharma, Inc. have signed a discovery partnership to develop off-the-shelf allogeneic T cell-based cancer therapies from stem cells.

At J.P. Morgan conference, the British company announced that Astellas has agreed to co-develop and co-commercialize stem-cell derived allogeneic CAR-T and TCR T-cell therapies against up to three targets. In contrast to current autologous T cell therapies, allogenic T cell therapies might be manufactured in a central facility reducing production cost significantly compared to autologous cell production and logistics.

Under the agreement, Adaptimmune will identify and validate new targets for generating target-specific T-cell receptors (TCRs), chimeric antigen receptors (CARs), and HLA-independent TCRs that recognize surface epitopes independently from the HLA profile of the tumour cell. Astellas subsidiary Universal Cells, Inc will provide its Universal Donor Cell and Gene Editing Platform, which makes use of a stem cell-tropic rAAV vector for engineering humanpluripotent stem cells to contain deletions, insertions, or point mutations at any genomic position.

Adaptimmune has been collaborating with Universal Cells since 2015 on development of gene-edited induced pluripotent stem cell (iPSC) lines that generate proprietary T-cell products without the use of feeder layers.

Under the agreement, Astellas will fund research up until completion of a Phase I trial for each candidate with US$7.5m per year. Subsequently, Astellas and Adaptimmune may opt for co-development and co-commercialization of the candidate, or independent development through a milestone and royalty bearing licence. Under the agreement, Astellas will also have the right to select two targets and develop allogeneic cell therapy candidates on its own.

In case of Astellas would develop the candidates on its own, Adaptimmune may receive up to$897.5m in payments. If Adaptimmune would do so, Astellas may receive up to US$552.5m. If the companies opt for co-commercialisation any T-cell therapy, costs and profits will be shared equally.

See more here:
Astellas and Adaptimmune team up in CAR-T development - European Biotechnology

Stem Cell Therapy Market Rising Demand for Digitization in Organizations and Growth till 2027 – Galus Australis

By adminJanuary 15, 2020Induced Pluripotent Stem Cells

The report provides in-depth analysis on the topic and discuss drivers, restraints and opportunities available in the market. The service is designed to help our clients in their decision support system. The analysis also cover the complete spectrum of the research topic to help our clients meeting their business objective.

Stem cell therapy is a technique which uses stem cells for the treatment of various disorders. Stem cell therapy is capable of curing broad spectrum of disorders ranging from simple to life threatening. These stem cells are obtained from different sources, such as, adipose tissue, bone marrow, embryonic stem cell and cord blood among others. Stem cell therapy is enables to treat more than 70 disorders, including degenerative as well as neuromuscular disorders. The ability of a stem cell to renew itself helps in replacing the damaged areas in the human body.

Download a Sample Report Explore further @https://www.theinsightpartners.com/sample/TIPHE100000991

Increase in the number of stem cell banking facilities and rising awareness on the benefits of stem cell for curing various disorders are expected to drive the market during the forecast period. Rise in number of regulations to promote stem cell therapy and increase in number of funds for research in developing countries are expected to offer growth opportunities to the market during the coming years.

Top Dominating Key Players:

1. MEDIPOST2. PHARMICELL Co., Ltd3. Holostem Terapie Avanzate S.r.l.4. Mesoblast Ltd5. U.S. Stem Cell, Inc.6. BIOTIME, INC.7. Lonza8. Caladrius9. Takeda Pharmaceutical Company Limited10. KOLON TISSUEGENE INC.

The stem cell therapy market is segmented based on type as, adult stem cell, embryonic stem cell induced pluripotent stem cell and others. The adult stem cells segment is further segmented as hematopoietic, umbilical cord, neuronal and mesenchymal stem cells. Based on treatment, the market is categorized as allogeneic and autologous. The market is categorized by application as, muscoskeletal, dermatology, cardiology, drug discovery & development and others.

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global stem cell therapy market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The stem cell therapy market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting stem cell therapy market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the stem cell therapy market in these regions.

Request for Buy Report @https://www.theinsightpartners.com/buy/TIPHE100000991

Reasons to Buy the Report:

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

The Insight partners,

Phone: +1-646-491-9876Email:sales@theinsightpartners.com

Visit link:
Stem Cell Therapy Market Rising Demand for Digitization in Organizations and Growth till 2027 - Galus Australis

Allele and Astellas Enter into an Expanded License for the Development of iPSC Lines – Yahoo Finance

By adminJanuary 15, 2020Induced Pluripotent Stem Cells

Allele Biotechnology and Pharmaceuticals, Inc. (President and CEO: Jiwu Wang, Ph.D., "Allele"), a San Diego-based private company, and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas"), through its Massachusetts-based subsidiary Astellas Institute for Regenerative Medicine (AIRM), entered into a licensing agreement to expand Astellas access to Alleles induced pluripotent stem cell (iPSC) technologies for various cell therapy programs.

Astellas, one of the largest pharmaceutical companies in Japan and already a leader in the development of cell-based therapeutics, has further dedicated to development of the field through its commitment to state-of-the-art iPS cell generation, modification, and manufacturing. iPSC lines can differentiate into all somatic tissue types, enabling a wide variety of therapeutic applications. The field of iPSC-derived cells has seen dramatic growth in clinical trials recently--the majority of the ~12 clinical trials around the world were initiated within the last 18 months and many more are upcoming.

Allele has been developing its core strength in reprogramming somatic cells into iPSCs with granted patents and the first commercial cGMP system it developed over the past 10 years. Allele also engages in more than a dozen different human tissue derivation activities through its own R&D efforts for internal programs and partnerships. To realize the unparalleled potential of iPSC, Alleles researchers and cGMP team are committed to setting up and validating cell assays for product quality control, genome analysis pipelines, closed-system automation for reprogramming, and machine learning in iPSC-related fields.

Under the terms of the new license agreement, Astellas will pay Allele upfront and milestones, product-based royalties, and potentially manufacture fees.

About AlleleAllele Biotechnology and Pharmaceuticals was founded in 1999. In 2015, the company completed an 18,000 square foot state-of-the-art facility in San Diego for the production of GMP-grade human iPSC lines. The facility also supports the production of tissue-specific cells differentiated from these iPSCs, including pancreatic beta cells, neural progenitor cells, and cardiomyocytes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200113005668/en/

Contacts

Allele Biotechnology and Pharmaceuticals, Inc.Daniel Catrondcatron@allelebiotech.com +1 858-587-6645

View post:
Allele and Astellas Enter into an Expanded License for the Development of iPSC Lines - Yahoo Finance

Researchers have managed to bio-print a functional mini-liver in 90 days – FLWL News

By adminJanuary 15, 2020Induced Pluripotent Stem Cells

Brazilian researchers claim to have bio-printed hepatic organoids. These are miniature versions of livers obtained from human blood cells. However, these mini-organs would be able to perform all the functions of a liver. This innovation gives new hope in terms of organ transplant.

A functional mini-liverIn their publication in the journal Biofabrication of November 27, 2019, researchers from the Human Genome and Stem Cell Institute in Sao Paulo (Brazil) indicated that they obtained a mini-liver through bio-printing. However, the latter would fulfill all the functions hoped for! These include the production of vital proteins, the storage of vitamins and the secretion of bile.

The researchers explained that they combined several bioengineering techniques. Indeed, the culture of pluripotent stem cells and cell reprogramming have been combined with 3D bio-printing. However, there is a difference compared to previous research. In fact, the cells were placed entirely in the bio-ink before being extruded. Previously, it was simply a matter of individual cells.

Relieve waiting for transplantNo less than 90 days were required, from collecting the patients blood to producing the tissue. First, the researchers reprogrammed the patients blood cells into induced pluripotent stem cells. Then, the differentiation of the cells made it possible to change them into liver cells. Finally, their spheroids may have been associated with bio-ink.

You should know that the project directors have bio-printed not one, but three mini-livers. Logically, the stem cells came from three different donors. The objective? Test the method then analyze the functionalities of the organs and the maintenance of cellular contact. As expected, the method worked much better than in the case of previous research incorporating individualized cells. The researchers said the technique could be replicated on a large scale.

Thus, this innovation could open up new hopes in terms of organ transplants. Indeed, the wait for an organ can be very long, which can be problematic. In China, tensions around the field of organ transplants have given rise to questionable research. In 2017, researchers said they wanted to clone pigs to recover their organs. The objective? To successfully transplant humans with these same organs and end the terrible waiting lists.

Lamia spent a couple of years interning at an organization that offered medical consultation before joining the editorial team at FLWL News. An enthusiastic fitness freak in the room, she offers the best amounts of insights and craft-based writing style to keep us up to date about the medicine industry, health and science.

Email:lamia@flwl.orgPhone: +1 512-845-8162

Read this article:
Researchers have managed to bio-print a functional mini-liver in 90 days - FLWL News

Orthobiology Market Innovative Technologies, Current And Future Trends – PharmiWeb.com

By adminJanuary 15, 2020Stem Cell Clinics

New York City, NY: Jan 15, 2020 Published via (Wired Release) The research report on the international Orthobiology market is a compilation of intelligent, broad studies research so one can assist players and stakeholders to make informed business choices in future. It gives precise and reliable suggestions for players to better address challenges inside the global Orthobiology market. Furthermore, it comes out as a powerful resource providing up to date and verified information and records on numerous aspects of the global Orthobiology market. Readers will be in a position to advantage deeper knowledge of the competitive panorama and its future scenarios, essential dynamics, and leading segments of the international Orthobiology market. Buyers of the file will have to get entry to correct PESTLE, SWOT, and other kinds of analysis on the global Orthobiology market.

The research analysis is a superb account of macroeconomic and microeconomic factors influencing the growth of the global Orthobiology market. This will help market players to make suitable changes in their approach towards attaining growth and maintaining their position in the industry. The global Orthobiology market is segmented as per sort of product, application, and geography. Each segment is evaluated in an exceptional element so that players can cognizance on high-boom areas of the global Orthobiology market and grow their sales boom. Even the competitive panorama is shed light upon for players to build powerful techniques and deliver a difficult opposition to other participants inside the global Orthobiology market.

For Better Understanding, Request A Free Pdf SampleCopy Of Orthobiology Market Here@ https://marketresearch.biz/report/orthobiology-market/request-sample

Our FREE SAMPLE COPY of the report gives a brief introduction to the research report outlook, TOC, list of tables and figures, an outlook to key players of the market and comprising key regions.

List of key players in Orthobiology Market: Inc., Smith & Nephew plc, Berkeley Advanced Biomaterials, Inc., Pioneer Surgical Technology, Inc., Bone Solutions, Stryker Corporation, Inc., Inc., Bone Biologics Corporation, Allograft Tissue Systems, Inc., Medtronic, Kinetic Concepts, Osiris Therapeutics, Baxter International Inc. and Inc..

Market Segmentation:

Global Orthobiology Market Segmentation, by Product: Bone Allograft, Stem Cell Therapy, Bone Graft Substitutes, Bone Growth Factors & Spinal Stimulation, Viscosupplementation. Global Orthobiology Market Segmentation, by End-user: Hospitals, Orthopaedic Clinics, Other End Users

Motivations to Purchase this Report:

The dissecting perspective of the Orthobiology market with the ongoing patterns and Porters 5 powers examination

Market elements which essentially think about the components, which can be inducing the present Orthobiology market situation, alongside development possibilities of the market inside the years to technique.

Orthobiology Market division examination, together with subjective and quantitative research becoming a member of the impact of economic and non-monetary elements

Territorial and nation level investigation coordinating the interest and deliver powers which can be affecting the improvement of the Orthobiology market

Aggressive scene together with the Orthobiology market provider of real gamers, along with the key techniques embraced for improvement in the previous five years to recognition.

Comprehensive company profiles overlaying the item contributions, key budgetary data.

A thorough projection of Orthobiology market performance throughout distinct areas is presented via self-explanatory graphic images, charts, figures, graphs, and tables that add weight to corporate presentation and marketing materials. Research is one in all for its type of global analyses of Orthobiology aspects which includes import and export status, earnings and gross margin globally for the forecast period 2020 2029.

The examine is a supply of reliable records on:Market segments and sub-segments, Market tendencies and Orthobiology market size cutting-edge traits/opportunities/challenges aggressive landscape, technological breakthrough cost chain and stakeholder analysis

Any Query? Fill Free To Inquire Here: https://marketresearch.biz/report/orthobiology-market/#inquiry

The local evaluation covers:

North America (the U.S. And Canada)

Latin America (Brazil, Peru, Mexico, Chile, and others)

Western Europe (Germany, Italy, Nordic countries, Belgium, U.K., France, Spain, Netherlands, and Luxembourg)

Eastern Europe (Poland and Russia)

Asia Pacific (China, ASEAN, Australia, India, Japan, and New Zealand)

The Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through giant primary studies (through interviews, surveys, and observations of pro analysts) and secondary research. The record also features a whole qualitative and quantitative assessment by way of analyzing facts amassed from industry analysts and market participants across key points in the industrys fee chain.

Highlights of the report: A whole backdrop analysis, which incorporates an assessment of the discerning market. Crucial update in market dynamics market segmentation up to the second or third level. Historical, present, and projected size of the Orthobiology market from the viewpoint of both price and volume. Reporting and calculation of the latest enterprise developments, market shares and business strategies of key players. Emerging niche segments and local markets. Objective estimation of the trajectory of the Orthobiology market. Recommendations to companies for reinforcing their foothold in the market

Browse More Insight Of This Orthobiology Market Research Report Enabled with Respective Tables and Figures at: https://marketresearch.biz/report/orthobiology-market/

Request customized copy of Orthobiology report

If you wish to discover greater info of the report or need customization, contact us. You can get an in-depth of the entire research here. If youve got any special requirements, please let us realize and we can provide you the report as you want.

About Us:

MarketResearch.Biz is a specialized market research, analytics, and solutions company, offering strategic and tactical support to clients for making well-informed business decisions. We are a team of dedicated and impassioned individuals, who believe strongly in giving our very best to what we do and we never back down from any challenge. The company offers services such as data mining, information management, and revenue enhancement solutions and suggestions. We cater to industries, individuals, and organizations across the globe, and deliver our offerings in the shortest possible turnaround time.

Mr. Benni Johnson

Prudour Pvt. Ltd.

420 Lexington Avenue,

Suite 300 New York City, NY 10170,

United States

Tel: 1-347-826-1876

Email ID: inquiry@marketresearch.biz

Website: https://marketresearch.biz/

This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us at contact@wiredrelease.com.

Read this article:
Orthobiology Market Innovative Technologies, Current And Future Trends - PharmiWeb.com

Curcumin Combined with Thalidomide Reduces Expression of STAT3 and Bcl | DDDT – Dove Medical Press

By adminJanuary 15, 2020Stell Cell Research

Mahnaz Mohammadi Kian, 1, 2 Mahdieh Salemi, 1, 2 Mohammad Bahadoran, 3 Atousa Haghi, 1, 4 Nasrin Dashti, 5 Saeed Mohammadi, 1, 2 Shahrbano Rostami, 1, 2 Bahram Chahardouli, 1, 2 Davood Babakhani, 1 Mohsen Nikbakht 1, 2

1Hematology Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran; 2Hematologic Malignancies Research Center, Tehran University of Medical Sciences, Tehran, Iran; 3Department of Biochemistry, Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran; 4Young Researchers & Elite Club Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; 5Department of Medical Laboratory Sciences, School of Allied Health Sciences, Tehran University of Medical Sciences, Tehran, Iran

Correspondence: Mohsen NikbakhtHematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, IranTel +982184902639Fax +982188004140Email m-nikbakht@sina.tums.ac.irNasrin DashtiDepartment of Medical Laboratory Sciences, School of Allied Health Sciences, Tehran University of Medical Sciences, Tehran, IranTel +989123583690Email dashti@tums.ac.ir

Introduction: Acute myeloid leukemia (AML) is a type of blood disorder that exhibits uncontrolled growth and reduced ability to undergo apoptosis. Signal transducer and activator of transcription 3 (STAT3) is a family member of transcription factors which promotes carcinogenesis in most human cancers. This effect on AML is accomplished through deregulation of several critical genes, such as B cell lymphoma-extra-large (BCL-XL) which is anti-apoptotic protein. The aim of this study was to evaluate the effect of curcumin (CUR) and thalidomide (THAL) on apoptosis induction and also the alteration of the mRNA expression level of STAT3 and BCL-XL mRNA on AML cell line compounds.Methods: The growth inhibitory effects of CUR and THAL and their combination were measured by MTT assay in U937 and KG-1 cell lines. The rates of apoptosis induction and cell cycle analysis were measured by concurrent staining with Annexin V and PI. The mRNA expression level of STAT3 and BCL-XL was evaluated by Real-Time PCR.Results: CUR inhibited proliferation and induced apoptosis in both KG-1 and U937 cells and this effect increased by combination with THAL. The expression level of STAT3 and BCL-XL was significantly down-regulated in KG-1 cells after treatment by CUR and THAL and their combination.Conclusion: Overall, our findings suggested that down-regulation of STAT3 and BCL-XL mRNA expression in response to CUR and THAL treatment lead to inhibition of cell growth and induction of apoptosis.

Keywords: acute myeloid leukemia, curcumin, thalidomide, STAT3, Bcl-xL

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Excerpt from:
Curcumin Combined with Thalidomide Reduces Expression of STAT3 and Bcl | DDDT - Dove Medical Press

Global Stem Cell Reconstructive Market 2019 Share, Trend, Segmentation and Forecast to 2025 – Instanews247

By adminJanuary 15, 2020Stell Cell Research

Global Stem Cell Reconstructive Market research Report 2019 may be a comprehensive business study on this state of business that analyses innovative ways for business growth and describes necessary factors like prime manufacturers, production worth, key regions and rate of growth. with growth trends, numerous stakeholders like investors, CEOs, traders, suppliers, analysis & media, international Manager, Director, President, SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization and others. This report focuses on Professional Global Stem Cell Reconstructive Market 2019-2025 volume and value at Global level, regional level and company level.

Global Stem Cell Reconstructive Market 2019 report provides key statistics on the market status of the Stem Cell Reconstructive Manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Stem Cell Reconstructive Industry. The Stem Cell Reconstructive industry report firstly announced the Stem Cell Reconstructive Market fundamentals: type applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on.

Request Exclusive Free Sample PDF Of This Report At https://dataintelo.com/request-sample/?reportId=113159

Stem Cell Reconstructive market competition by top manufacturers/ Key player Profiled:Osiris TherapeuticsNuVasiveCytori TherapeuticsTakeda (TiGenix)CynataCelyadMedi-postAnterogenMolmedAnd More

Stem Cell Reconstructive Market is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2025, from xx million US$ in 2019, according to a new study.

Stem Cell Reconstructive Market Segment by Type covers:Embryonic Stem CellAdult Stem Cell

Stem Cell Reconstructive Market Segment by Applications can be divided into:HospitalsResearch InstitutesOthers

Regional analysis covers:North America (USA, Canada and Mexico)Europe (Germany, France, UK, Russia and Italy)Asia-Pacific (China, Japan, Korea, India and Southeast Asia)South America (Brazil, Argentina, Columbia etc.)Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

This report focuses on the Stem Cell Reconstructive in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

For More Information on this report, Request Inquiry At https://dataintelo.com/enquiry-before-buying/?reportId=113159

Key questions answered in the report:What will the market growth rate of Stem Cell Reconstructive market?What are the key factors driving the Global Stem Cell Reconstructive market?Who are the key manufacturers in Stem Cell Reconstructive market space?What are the market opportunities, market risk and market overview of the Stem Cell Reconstructive market?What are sales, revenue, and price analysis of top manufacturers of Stem Cell Reconstructive market?Who are the distributors, traders and dealers of Stem Cell Reconstructive market?What are the Stem Cell Reconstructive market opportunities and threats faced by the vendors in the Global Stem Cell Reconstructive industries?What are sales, revenue, and price analysis by types and applications of Stem Cell Reconstructive market?What are sales, revenue, and price analysis by regions of Stem Cell Reconstructive industries?

Key Benefits Major countries in each region are mapped according to individual market revenue. Comprehensive analysis of factors that drive and restrict the market growth is provided. The report includes an in-depth analysis of current research and clinical developments within the market. Key players and their key developments in the recent years are listed.And More.

The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, growth rate of Stem Cell Reconstructive market in 2025 is also explained. Additionally, type wise and application wise consumption tables and figures of Stem Cell Reconstructive market are also given.

To Buy this Report, Visit https://dataintelo.com/checkout/?reportId=113159

Objective of Studies: To provide strategic profiling of key players in the market, comprehensively analysing their core competencies, and drawing a competitive landscape for the market. To provide insights about factors affecting the market growth. To analyse the Stem Cell Reconstructive market based on various factors- price analysis, supply chain analysis, porter five force analysis etc. To provide detailed analysis of the market structure along with forecast of the various segments and sub-segments of the Global Stem Cell Reconstructive market. To provide country level analysis of the market with respect to the current market size and future prospective. To provide country level analysis of the market for segment by application, product type and sub-segments. To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, and Rest of the World. To track and analyse competitive developments such as joint ventures, strategic alliances, new product developments, and research and developments in the Global Stem Cell Reconstructive market.

For Best Discount on purchasing this report, Visit https://dataintelo.com/ask-for-discount/?reportId=113159

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info DataInteloName Alex MathewsEmail [emailprotected]Website https://dataintelo.comAddress 500 East E Street, Ontario, CA 91764, United States.

See the original post:
Global Stem Cell Reconstructive Market 2019 Share, Trend, Segmentation and Forecast to 2025 - Instanews247

Study: Mutations in stem cells of young donors can be passed to recipients – STAT

By adminJanuary 15, 2020Stem Cell Treatment

Doctors use stem cell transplants to treat patients with certain cancers or blood disorders. And donors, whose blood or bone marrow is used for the procedures, are typically young, for a variety of reasons.

But a pilot study released Wednesday raised the possibility that such donors are also passing along mutations in stem cells that could lead to health problems for some recipients.

The study found that nearly 45% of younger donors had mutations in the transplanted stem cells that could raise the risk of conditions that are sometimes seen in recipients, a higher rate than presumed. Researchers also reported that some of these mutations persisted and proliferated in the recipients bone marrow for at least a year.

What remains unknown is whether those mutations are actually contributing to health problems for recipients.

The study was small, with just 25 donors included and was not large enough and did not last long enough to determine whether people who received cells with these mutations had worse outcomes after a transplant than recipients who got cells without those mutations. Dr. Todd Druley, the senior author of the paper, which was published in the journal Science Translational Medicine, emphasized that patients should continue to receive these stem cells to treat their leukemias or anemias when recommended.

What were trying to say is that now we can provide surveillance before, during, and after a bone marrow transplant so that if theres an increased risk for a particular outcome, treatment for that and surveillance for that can be instituted sooner, said Druley, a pediatric oncologist at Washington University in St. Louis.

Researchers not involved with the study praised its technical prowess, and said it was worth investigating further to see if the transplanted mutations did lead to worse outcomes for recipients projects that Druley and his colleagues have underway. But they agreed it should not yet change clinical practice.

Donors are already screened to make sure they have a clean bill of health and make for a good match for recipients, based on their immune systems. Experts said it would be unrealistic to screen every potential donor for the kinds of mutations Druley and his team found. Those mutations were infrequent, and it wasnt clear they posed health risks to recipients.

We know that younger donors are better than older donors. We know that the better the donor the better the outcomes. We dont know how these ultra-low level mutations affect outcomes at all, said Dr. Corey Cutler, the medical director of the adult stem cell transplantation program at Dana-Farber Cancer Institute.

Hematopoietic stem cells generate blood and immune cells. They are sometimes transplanted into patients with certain blood or immune disorders or cancers whose own cells have been wiped out by chemotherapy, essentially restocking the recipients with healthy cells.

But recipients of these transplants sometimes experience graft versus host disease (when the transplant attacks the recipients tissues), heart or immune conditions, or even secondary cancers. Some experts have suspected these conditions might be caused by mutations in donor stem cells, among other factors. Its in part why they favor younger donors, who are expected to have fewer mutations than older donors. (Donors from 18 to 44 account for 86% of transplants for unrelated patients. Relatives often make for better donors because they are more likely to be matched to recipients based on immune system molecules.)

Most of these mutations are probably benign. But its possible that other mutations not only pose a health risk, but also give their host cells a boost over other cells, helping them proliferate over time. That might mean someone who is 40 could have a bad mutation in one in 5,000 cells, but by the age of 50, it could be in one in 50 cells, Druley explained.

The challenge is detecting those mutations. Standard sequencing technology may pick up mutations if they appear in just a small percentage of cells, but for young donors, it would be like finding the few pebbles in a beach full of sand.

Next-generation sequencing is good if you want to find a mutation thats in 20% of cells youre looking at, or even 5%, Druley said. Were looking at mutations that are one in a thousand, or down to one in ten thousand.

For the new study, Druley and colleagues trained a more powerful tool they call error-corrected sequencing on the cells of the 25 donors, who ranged from 20 to 58 years old. (Fifty-eight would be considered older donors, but the median age of the donors in the study was 26.) They looked for mutations in 80 genes in particular, including genes that, when mutated, are associated with leukemia.

What they found: 11 donors had a collective 19 mutations that were not picked up by standard sequencing technology 16 of which were pathogenic, meaning disease causing.

The researchers also studied the recipients, finding that 14 of the 19 mutations had engrafted, or been taken up by the recipient and started to generate other cells, and were still there a year after the transplant. Thirteen of these mutations were pathogenic.

Researchers said it made sense that younger adults had these types of mutations, even if scientists hadnt previously been able to spot them.

Its known that mutations accumulate over time, said Dr. Ross Levine, a leukemia specialist at Memorial Sloan Kettering Cancer Center, who was not involved in the new study. The question has always been in other scenarios if you can detect these clones at earlier or in different contexts, and if they mean anything.

The new study was not set up to answer that last question.

Thats the next phase of this research, Druley said. Some of these mutations, if theyre going to have an effect, may not have an effect for many, many years. And we had a small population. So we didnt have enough numbers or enough time.

Outside researchers said that if these stem cell mutations do contribute to diseases once transferred to recipients, it might take so long or happen so infrequently that it would be difficult to study. Dana-Farbers Cutler said that, for example, cases of donor-derived leukemia when the recipient develops blood cancer after a transplant occur in less than 1% of transplants from unrelated donors.

If the mutations do increase the likelihood of complications in recipients, then why arent they posing a problem for the donors themselves? That might also be tied to the prevalence of these mutations, the researchers said.

In donors, these mutations might appear in, say, 1% of cells, and there is competition among cells of all different types of genetic variants to multiply. Plus, donors have healthy immune systems that can help suppress bad actors.

But if cells with these mutations make their way into recipients who have had their own cells blasted away with chemotherapy, its a new race. The mutations might give them some advantage to multiply faster than other cells that were transplanted. And as the percentage of cells with these mutations rises, they might be more likely to cause disease.

When you have these mutations in a host, it may take decades for them to expand to the point of causing issues, Levine said. In a recipient, however, its almost like youve reset the playing field.